Unicycive Therapeutics (UNCY) has a high likelihood of extending the patent life of its lead drug candidate, oxylanthanum carbonate (OLC), to 2035. While the core patents for OLC are currently set to expire in 2031, the company is actively seeking Patent Term Extensions (PTE) based on the regulatory review process.
Key Factors for Extension Chances:
Strong Patent Portfolio: OLC is protected by a portfolio covering its composition of matter and nanoparticle technology, with initial protection to 2031.
Regulatory Status: The company resubmitted its New Drug Application (NDA) in December 2025 following a Type A meeting with the FDA to resolve manufacturing issues.
PDUFA Date: The FDA has set a target action date (PDUFA) of June 27, 2026, for the NDA resubmission.
Potential for Extension: Based on the time spent in clinical trials and the FDA approval process, a patent term extension up to 2035 is considered possible, extending the commercial runway.
Market Data 
Markets 
AI
